Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases

Nicholas Schrader*, JC DUIPMANS, Bouwe Molenbuur, André Wolff, Marcel F. Jonkman

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

9 Citaten (Scopus)
311 Downloads (Pure)


Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved
Originele taal-2English
Pagina's (van-tot)922-924
Aantal pagina's3
Nummer van het tijdschrift4
StatusPublished - apr-2019

Citeer dit